Results 91 to 100 of about 24,049 (149)
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial. [PDF]
Blood AdvHawkes EA, Palmer JB, Khor R, Lee ST, Burgess M, Law SC, Gandhi MK, Chong G, Shortt J, Chowdhury R, Swain F, Churilov L, MacManus M, Smith C, Scott FE, Martynchyk A, Barraclough A, Manos K, Scott AM, Keane C. +19 moreeuropepmc +1 more sourceSupplementary Table S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Chang Gon Kim, Min Hee Hong, Dahee Kim, Brian Hyohyoung Lee, Hyunwook Kim, Chan‐Young Ock, Geoffrey Kelly, Yoon Ji Bang, Gamin Kim, Jung Eun Lee, Chaeyeon Kim, Se‐Heon Kim, Hyun Jun Hong, Young Min Park, Nam Suk Sim, Heejung Park, Jin Woo Park, Chang Geol Lee, Kyung Hwan Kim, Goeun Park, Inkyung Jung, Dawoon Han, Jong Hoon Kim, Junha Cha, Insuk Lee, Mingu Kang, Heon Song, Chiyoon Oum, Seulki Kim, Sukjun Kim, Yoojoo Lim, Seunghee Kim‐Schulze, Miriam Mérad, Sun Och Yoon, Hyun Je Kim, Yoon Woo Koh, Hye Ryun Kim +36 moreopenalex +1 more sourceReal-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer. [PDF]
OncologistHuang WK, Tang YJ, Wu CE, Hou MM, Hsu HC, Su PJ, Chiang NJ, Chen SC, Yeh CN, Chen JS, Chen MH, Hsieh CH, Chou WC. +12 moreeuropepmc +1 more sourceEnhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC. [PDF]
NPJ Precis OncolLesniak J, Schick M, Kunzke T, Pollastri F, Vigueras-Guillén JP, Hessel H, Haneder S, Sontakke P, DaCosta K, Alleze R, Zimmermann J, Kapil A, Brieu N, Shumilov A, Sade H, Barrett JC, Schmidt G, Stewart R. +17 moreeuropepmc +1 more sourceA Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Andrew L. Coveler, Matthew J. Reilley, Mark M. Zalupski, Teresa Macarulla, Christos Fountzilas, Mariano Ponz‐Sarvisé, Adnan Nagrial, Nataliya V. Uboha, Sophia Frentzas, Michael J. Overman, Anne M. Noonan, Wells A. Messersmith, Nick Pavlakis, Niharika B. Mettu, Ina Bisha, Ying Wang, Paul Smith, Elina Murtomaki, Agata A. Bielska, Véronique Bragulat, Zachary A. Cooper, Rakesh Kumar, David R. Spigel +22 moreopenalex +1 more sourceSupplementary Figure S1 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Yvette Drew, Jae‐Weon Kim, Richard T. Penson, David M. O’Malley, Christine Parkinson, Patricia Roxburgh, Ruth Plummer, Seock‐Ah Im, Martina Imbimbo, Michelle Ferguson, Ora Rosengarten, Neeltje Steeghs, Min Hwan Kim, Einav Nili Gal‐Yam, Daliah Tsoref, Jae‐Hoon Kim, Benoît You, Maja J.A. de Jonge, Roy Lalisang, Eelke Gort, Sara Bastian, Kassondra Meyer, Laura Feeney, Nigel Baker, Mei-Lin Ah-See, Susan M. Domchek, Susana Banerjee +26 moreopenalex +1 more sourceNeoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A Systematic Review of Current Evidence. [PDF]
Eur Urol Open SciSuartz CV, de Lima RD, de Almeida LS, Liebl B, Lopes RI, Branquinho Reis GB, Henry Sant'Anna PV, Faris de Campos VD, Mota JM, Lima Aguiar Melão BV, Nahas WC, Shahrour W, Shabana W, Ribeiro-Filho LA, Toren P, Fradet V. +15 moreeuropepmc +1 more sourceUK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme. [PDF]
Cancers (Basel)Daniels H, Hassan M, Babiker O, Rowley W, Qaisar A, Phillips E, Griffin E, Bell C, Baraka B, Acharige S, Aquino M, Plant R, Mencel J, Chan S, Parslow D, Arora A, Scott-Brown M, Khakoo S, Braconi C, Palmer D, Ma YT, Sivakumar S. +21 moreeuropepmc +1 more source
